Immunotherapy shot could replace IV drip for advanced head and neck cancer
NCT ID NCT05751486
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This phase I study is testing a subcutaneous (under the skin) injection of toripalimab, an immunotherapy drug, for people with advanced nasopharyngeal carcinoma. The trial compares the new injection to the standard intravenous (IV) version, looking at safety, tolerability, and how the drug moves through the body. Participants may receive the injection alone or combined with chemotherapy. The goal is to see if the shot is a safe and effective alternative to the IV drip.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- toripalimab (subcutaneous injection)
- What this could lead to
- If successful, this could offer a more convenient way to deliver immunotherapy for advanced nasopharyngeal carcinoma, potentially improving patient comfort and access.
- What could go wrong
- This is an early phase I trial with a small number of participants, so safety and effectiveness are not yet established. The subcutaneous form may not work as well as the IV version or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China